<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107479">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01776463</url>
  </required_header>
  <id_info>
    <org_study_id>01A10101</org_study_id>
    <nct_id>NCT01776463</nct_id>
  </id_info>
  <brief_title>A Healthy Subject Study With Z-360 and Placebo</brief_title>
  <official_title>A Single Centre, Randomized, Double-blind, Ascending Dose, Placebo-controlled, and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Z-360 and Placebo in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zeria Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zeria Pharmaceutical</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics
      (including food effect) of single and multiple doses of Z-360 in healthy Japanese subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single centre, randomized, double-blind, placebo-controlled, parallel-group, and
      food effect study.This is three parts study. The purpose of the first part (Part 1) is the
      evaluation of the safety, tolerability, and pharmacokinetics after single ascending doses of
      Z-360.The second part (Part 2 ) is the evaluation of the pharmacokinetics of food effect of
      Z-360.The third part (Part 3) is the evaluation of the safety, tolerability, and
      pharmacokinetics after multiple ascending doses of Z-360.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>General safety and tolerability endpoints: (Adverse events, Vital signs, 12-lead ECG and clinical laboratory safety tests)</measure>
    <time_frame>up to 6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics of single and multiple doses of Z-360 in healthy subjects</measure>
    <time_frame>up to 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>pK (AUC, Cmax, Tmax, T1/2, MRT, CL/F, V/F)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Z-360</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1)Single dose study (60, 120, 240, 480, 720mg), 2)Food effect study(120mg), 3)Multiple doses study(120, 240mg (BID))</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1)Single dose study, 2)Multiple doses study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Z-360</intervention_name>
    <arm_group_label>Z-360</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male subjects between 20 to 49 years of age inclusive

          2. Body mass index (BMI) within the range 17.6 to 26.4 kg/m2 inclusive

          3. The subject is capable of giving written informed consent prior to admission into
             this study

        Exclusion Criteria:

          1. History or presence of drug hypersensitivity, drug dependence, narcotic dependence or
             alcohol dependence

          2. History or presence disease of digestive, liver, kidney, blood, cardiovascular,
             neuropsychiatric which may affect participation or results of this study

          3. Positive test for Hepatitis B surface antigen, Hepatitis C antibody, HIV antigen
             antibody or Serological test for syphilis

          4. Use of any medication within 1 week prior to dosing

          5. Received any investigational drugs with new active ingredients within 16 weeks prior
             to dosing the study or received any investigational drugs in other clinical studies
             within 12 weeks

          6. Whole blood collection exceeding 200 mL within 4 weeks, apheresis within 2 weeks, or
             blood withdrawal exceeding 400 mL within 12 weeks (blood donation, etc)  prior to
             dosing

          7. Others, patients who are unfit for the study as determined by the attending physician
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eri Sato, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sumida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sumida</name>
      <address>
        <city>Sumida-ku</city>
        <state>Tokyo</state>
        <zip>130-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 30, 2013</lastchanged_date>
  <firstreceived_date>January 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Z-360</keyword>
  <keyword>Japanese</keyword>
  <keyword>pK</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
